WO2008112297A3 - Methods of treating cancer by interfering with igf-i receptor signaling - Google Patents
Methods of treating cancer by interfering with igf-i receptor signaling Download PDFInfo
- Publication number
- WO2008112297A3 WO2008112297A3 PCT/US2008/003393 US2008003393W WO2008112297A3 WO 2008112297 A3 WO2008112297 A3 WO 2008112297A3 US 2008003393 W US2008003393 W US 2008003393W WO 2008112297 A3 WO2008112297 A3 WO 2008112297A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igf
- treating cancer
- interfering
- methods
- receptor signaling
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Abstract
The invention includes methods of reducing proliferation, causing apoptosis and treating cancer through the inhibition of ASM, the disruption of lipid rafts and the interference with IGF-IR and Racl signaling using a variety of compounds including siRNA, anti-ASM antibodies, anti-ceramide antibodies, short- chain ceramide derivatives, desipramine, clomipramine, mangostin and/or sphingomyelin substrate analogues.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90667307P | 2007-03-13 | 2007-03-13 | |
US60/906,673 | 2007-03-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008112297A2 WO2008112297A2 (en) | 2008-09-18 |
WO2008112297A3 true WO2008112297A3 (en) | 2008-10-30 |
Family
ID=39760296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/003393 WO2008112297A2 (en) | 2007-03-13 | 2008-03-13 | Methods of treating cancer by interfering with igf-i receptor signaling |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008112297A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2363394B2 (en) * | 2010-01-19 | 2012-01-31 | Universidad De Sevilla | USE OF AMITRIPTILINE AS AN ANTITUMORAL AGENT FOR THE TREATMENT OF LUNG CANCER. |
WO2012036180A1 (en) * | 2010-09-16 | 2012-03-22 | 株式会社エコリソース研究所 | Xanthone derivative and use thereof |
CL2011000273A1 (en) | 2011-02-08 | 2011-06-17 | Univ Pontificia Catolica Chile | Use of a phosphatidic acid phosphohydrolase enzyme (pap) inhibitor or combination of inhibitors, in which the inhibitor is d (+) propranolol, and the combination is racemic mixture of propranolol od (+) propranolol together with desipramine, to prepare a Useful medicine in the treatment of cancer. |
CN105218507B (en) * | 2015-09-30 | 2020-10-02 | 中国药科大学 | 1, 3, 6, 7-tetrahydroxy xanthone derivative and preparation method and application thereof |
BR112023024640A2 (en) * | 2021-05-27 | 2024-02-27 | Isu Abxis Co Ltd | ANTIBODY THAT SPECIFICALLY BINDS TO THE ASM PROTEIN |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228276A1 (en) * | 2002-04-09 | 2003-12-11 | Pitossi Fernando Juan | Neuroprotective and neurogenerative effects of the long-term expression of TNF alpha in the substantia nigra and a new animal model for Parkinson's disease |
US20040247603A1 (en) * | 2000-12-22 | 2004-12-09 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation |
US20040259816A1 (en) * | 2002-10-01 | 2004-12-23 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
US20050002865A1 (en) * | 1996-10-28 | 2005-01-06 | Amersham Health As | Diagnostic/therapeutic agents |
US20050209219A1 (en) * | 2002-08-23 | 2005-09-22 | Erich Gulbins | Prophylaxis and treatment of infectious diseases |
US20060003968A1 (en) * | 2004-04-02 | 2006-01-05 | Jeremy Green | Azaindoles useful as inhibitors of rock and other protein kinases |
-
2008
- 2008-03-13 WO PCT/US2008/003393 patent/WO2008112297A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050002865A1 (en) * | 1996-10-28 | 2005-01-06 | Amersham Health As | Diagnostic/therapeutic agents |
US20040247603A1 (en) * | 2000-12-22 | 2004-12-09 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation |
US20030228276A1 (en) * | 2002-04-09 | 2003-12-11 | Pitossi Fernando Juan | Neuroprotective and neurogenerative effects of the long-term expression of TNF alpha in the substantia nigra and a new animal model for Parkinson's disease |
US20050209219A1 (en) * | 2002-08-23 | 2005-09-22 | Erich Gulbins | Prophylaxis and treatment of infectious diseases |
US20040259816A1 (en) * | 2002-10-01 | 2004-12-23 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
US20060003968A1 (en) * | 2004-04-02 | 2006-01-05 | Jeremy Green | Azaindoles useful as inhibitors of rock and other protein kinases |
Non-Patent Citations (2)
Title |
---|
HAMADA ET AL.: "Biological Activities of a-Mangostin Derivatives against Acidic Sphingomyelinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, pages 3151 - 3153, XP002728402, DOI: doi:10.1016/S0960-894X(03)00719-4 * |
OKAMOTO ET AL.: "Inhibitory Regulation of Rac Activation, Membrane Ruffting, and Cell Migration by the G Protein-Coupled Sphingosine-1-Phosphate Receptor EDG5 but not EDG1 Or EDG3", MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 24, 2000, pages 9247 - 9261, XP002951031 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008112297A2 (en) | 2008-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008083252A3 (en) | Methods of use for cyclopamine analogs | |
WO2007134086A3 (en) | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis | |
MX2009012561A (en) | Stevioside polymorphic and amorphous forms, methods for their formulation, and uses. | |
WO2012099973A3 (en) | Compositions and methods for treating cancer | |
SG169988A1 (en) | Rnai inhibition of alpha-enac expression | |
WO2007098474A8 (en) | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists | |
GB0812642D0 (en) | Compounds | |
MX2011006334A (en) | Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c] [1,2] oxaborol-1-ol. | |
MX2009008660A (en) | Method for the preparation of therapeutically valuable triphenylbutene derivatives. | |
EA200971068A1 (en) | TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS | |
MX2010005986A (en) | Grain products having a potent natural sweetener and a bulking agent. | |
MX339300B (en) | Small molecule inhibitors of n-terminus activation of the androgen receptor. | |
WO2008112297A3 (en) | Methods of treating cancer by interfering with igf-i receptor signaling | |
WO2011006035A3 (en) | Bis-ketoiminate copper precursors for deposition of copper-containing films | |
WO2010027150A3 (en) | New preparation of hydroxychloroquine | |
TW200833649A (en) | Method for the preparation of hydroxyadamantanamine | |
MX2009009490A (en) | Novel prodrugs. | |
WO2008060693A3 (en) | Tetracyclic imidazole analogs | |
WO2008156012A1 (en) | CANCER REMEDY CONTAINING MORTALIN siRNA | |
AU2009235634A8 (en) | Substituted sulfonamide derivatives | |
MX2011012022A (en) | Bisazo compounds. | |
MX2009011787A (en) | Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof. | |
WO2008092928A9 (en) | NOVEL ß-LACTAM ANTIBIOTICS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | |
UA34487U (en) | Aquananomagnesium | |
WO2009147632A3 (en) | New compounds for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08742085 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08742085 Country of ref document: EP Kind code of ref document: A2 |